EGFR mutation

Epidermal growth factor receptor (EGFR) mutation can be expressed in a large proportion of non-small cell lung carcinomas (NSCLC). However, certain subtypes such as invasive mucinous adenocarcinoma of the lung can have very low expression.

The presence of this mutation can be assessed on biopsy samples. Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that regulates signaling pathways to control cellular proliferation. It belongs to the erbB family of closely related receptor tyrosine kinases.

There is also some (but not 100% 5) mutual exclusivity with ALK gene arrangements.

EGFR is not to be confused with the estimated glomerular filtration rate, which shares the same acronym but with a lower case "e": eGFR. 

Useful for assessing the suitability of certain anti-cancer drugs (tyrosine kinase inhibitors) that inhibit EGFR such as gefitinib (IressaTM) ,erlotinib (TarcevaTM) and afatinib (GilotrifTM7.

Not to be confused with

Article information

rID: 69167
System: Oncology, Chest
Section: Pathology
Synonyms or Alternate Spellings:
  • Epidermal growth factor receptor (EGFR) mutations
  • Epidermal growth factor receptor mutation
  • Epidermal growth factor receptor(EGFR) mutation

ADVERTISEMENT: Supporters see fewer/no ads

Cases and figures

  • Case 1: multifocal EGFR-mutated adenocarcinoma
    Drag here to reorder.
  • Case 2
    Drag here to reorder.
  • Updating… Please wait.

     Unable to process the form. Check for errors and try again.

     Thank you for updating your details.